D-0560-2023 Class II Terminated
FDA drug recall D-0560-2023 was initiated by PD-Rx Pharmaceuticals, Inc. on Apr 6, 2023 and is designated Class II. Reason for recall: CGMP deviations. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 520 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 10, 2023
- Initiation Date
- Apr 6, 2023
- Termination Date
- Apr 30, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 520 bottles
Product description
Simvastatin USP 20 mg, Rx only, Intas Pharm. Limited Ahmedabad 380 054 India Pkg By: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127 a) 30 count-bottles (NDC 43063-008-30), b) 90 count-bottles (NDC: 43063-0008-90)
Reason for recall
CGMP deviations.
Distribution pattern
Nationwide in the US.
Code information
Lots: a) G22B32, D22B92, D22F82, Exp. 06/30/23; G22F41, J22F25, L22C14, Exp. 01/31/24; D22B92, D22F82 Exp. 06/30/23; B22A12, Exp. 03/31/23 b) H22A32, I22E83, J22E94, K22E34 Exp. 01/31/24; C22F31, D22G16, E22D75, F22E06, Exp. 06/30/23; L21E09, B22C61, Exp. 01/31/23.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0560-2023
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026